Is Larazotide Acetate safe?

In the doses and durations studied in trials, larazotide has shown a favorable safety profile with no severe drug-related adverse events, consistent with its design as a locally acting peptide that is not meant to be absorbed systemically. That said, safety data comes from monitored clinical trials, not from unregulated, self-sourced "research peptide" products of unverified purity and dosing accuracy — which is a different risk profile entirely.

It depends which trial. A mid-size Phase 2b trial in 2015 found a modest symptom benefit at one specific dose (0.5 mg), which is why the drug advanced to Phase 3. But the pivotal, larger Phase 3 trial (CedLara, ~525 patients) was stopped early in 2022 after an interim analysis showed it was not going to beat placebo — the sponsor, 9 Meters Biopharma, concluded the trial could not succeed and discontinued it. The honest summary is: promising early signal, confirmatory failure. It has not demonstrated efficacy at the standard a drug needs to clear for approval.

Because "research peptide" sellers operate in a market that does not require proof of efficacy or FDA approval to sell a peptide labeled "for research use only." Larazotide has a real, citable clinical trial history and a scientific-sounding mechanism ("zonulin antagonist"), which gives sellers plenty of legitimate-looking material to build marketing around — even though the actual pivotal trial outcome was negative. The gap between "this has been in real Phase 3 trials" and "this was shown to work" is exactly where the marketing operates.

The zonulin hypothesis itself is legitimate published science, but the commercial blood tests marketed to consumers to measure "zonulin levels" are on much shakier ground. Multiple independent validation studies have found that popular commercial zonulin ELISA kits do not reliably detect zonulin or its proposed precursor, and instead pick up unrelated proteins like properdin. That matters here because a lot of the retail pitch for larazotide is "test your zonulin, see it's high, take a zonulin blocker" — a chain of reasoning that is weaker at both the diagnostic and treatment-efficacy ends than it is presented.

The celiac disease program that drove its Phase 3 trial has been discontinued. Separately, academic researchers at Mass General Brigham found benefit in a small trial of larazotide for children with MIS-C (a severe post-COVID inflammatory condition) and, as of 2026, are running a Phase 2 trial exploring it for long COVID gastrointestinal symptoms. These are independent academic investigations into new indications, not a continuation of the original celiac drug-development program, and none of it constitutes approval for any use.